Q3 2025 · —
Revenue$12.34M$12.34M no prior Q3 2024 on file+220.7% vs Q2 2025
Net Income-$37.00K-$37.00K no prior Q3 2024 on fileN/M vs Q2 2025
EPS Diluted$0.00$0.00 no prior Q3 2024 on fileN/M vs Q2 2025
Operating Income-$213,000—
Operating Cash Flowderived$1,133,000—
Free Cash Flowderived$833,000—
Margins · derived
Operating margin-1.7%
Net margin-0.3%
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
no prior Q3 2024 on file
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Atrium Therapeutics, Inc. · CIK 2093101 · Engraved from SEC EDGAR